Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...
Solid Biosciences (NASDAQ:SLDB – Free Report) had its price objective boosted by Chardan Capital from $15.00 to $16.00 in a report published on Wednesday morning,Benzinga reports. The brokerage ...
Zacks.com on MSN4d
Biotech Stock Roundup: MRNA's Q4 Results, GILD's Update & Other NewsIt was a busy week for the biotech sector. While the fourth-quarter earnings season continues, other pipeline and regulatory ...
Boston, USA-based biotech Solid Biosciences saw its shares rocket 36% to $5.48 yesterday, after the precision genetic ...
In a report released today, Gena Wang from Barclays maintained a Buy rating on Solid Biosciences (SLDB – Research Report), with a price target ...
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
JMP Securities analyst Silvan Tuerkcan reiterated a Buy rating on Solid Biosciences (SLDB – Research Report) today and set a price target of ...
Hosted on MSN5d
Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's Behind The Move?Solid Biosciences Inc. (SLDB) shares surged more than 31% on Tuesday, their best session since January 2024, and extended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback